"Interferon beta-1b" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068576
|
| MeSH Number(s) |
D12.644.276.374.440.890.275.750 D12.776.467.374.440.890.275.750 D23.529.374.440.890.275.750
|
| Concept/Terms |
Interferon beta-1b- Interferon beta-1b
- beta-1b, Interferon
- Beta-IFN-1b
- Interferon Beta, Ser(17)
- Ser(17) IFN-beta
- Serine(17) Interferon Beta
- Interferon beta 1b
- 1b, Interferon beta
- beta 1b, Interferon
- IFN-Beta Ser
- Interferon Beta, Serine(17)
|
Below are MeSH descriptors whose meaning is more general than "Interferon beta-1b".
Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1b".
This graph shows the total number of publications written about "Interferon beta-1b" by people in this website by year, and whether "Interferon beta-1b" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon beta-1b" by people in Profiles.
-
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
-
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
-
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
-
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71.
-
Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study. Eur Neurol. 2014; 71(3-4):173-9.
-
The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
-
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol. 2013 Jul; 260(7):1838-45.
-
Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
-
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
-
Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies. J Neuroinflammation. 2012 Jun 15; 9:129.